Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Total Assets
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) holds total assets worth $2.79 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Liminatus Pharma, Inc. Class A Common Stock - Total Assets Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's total assets have evolved over time, based on quarterly financial data. Also see LIMN company net worth for the company's overall valuation and market capitalisation.
Liminatus Pharma, Inc. Class A Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Liminatus Pharma, Inc. Class A Common Stock's total assets of $2.79 Million consist of 97.6% current assets and 2.4% non-current assets. Review LIMN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LIMN stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Liminatus Pharma, Inc. Class A Common Stock's current assets represent 97.6% of total assets in 2025, an increase from 0.2% in 2021.
- Cash Position: Cash and equivalents constituted 65.9% of total assets in 2025, up from 0.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Total Assets
Key competitors of Liminatus Pharma, Inc. Class A Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Liminatus Pharma, Inc. Class A Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 766.66 | 0.08 |
| Quick Ratio | 0.96 | 766.66 | 0.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-110.88K | $811.60K | $-4.25 Million |
Liminatus Pharma, Inc. Class A Common Stock - Advanced Valuation Insights
This section examines the relationship between Liminatus Pharma, Inc. Class A Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 13.49 |
| Asset Growth Rate (YoY) | -81.9% |
| Total Assets | $512.79K |
| Market Capitalization | $6.92 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Liminatus Pharma, Inc. Class A Common Stock's assets at a significant premium (13.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Liminatus Pharma, Inc. Class A Common Stock's assets decreased by 81.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Liminatus Pharma, Inc. Class A Common Stock (2021–2025)
The table below shows the annual total assets of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $512.79K | -81.87% |
| 2024-12-31 | $2.83 Million | -37.17% |
| 2023-12-31 | $4.50 Million | -70.93% |
| 2022-12-31 | $15.49 Million | -94.40% |
| 2021-12-31 | $276.44 Million | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.